Application of extracellular vesicles derived from amniotic epithelial cells in promoting hair growth

By using extracellular vesicle active factors derived from amniocentesis cells to activate key signaling pathways, the problem of poor effectiveness of existing hair loss treatment methods is solved, and the effect of promoting hair growth and improving skin structure is achieved.

CN115531419BActive Publication Date: 2024-11-15XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211229013.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-08
Publication Date
2024-11-15
Estimated Expiration
2042-10-08

AI Technical Summary

Technical Problem

Existing hair loss treatments, such as drug treatment and hair follicle transplantation, are ineffective and have side effects and high cost issues that cannot meet the satisfaction of most patients, and the results of drug treatment are usually temporary.

Method used

Extracellular vesicles derived from amniocentesis cells are used as active factors to promote the expression of β-catenin, Lef1, Gli1, PTCH1 and activate the WNT and Shh signaling pathways, thereby promoting hair follicles from rest to growth phase, thereby promoting hair growth.

Benefits of technology

Effectively promote hair growth, improve skin tissue structure, improve hair follicle growth rate and hair thickening, providing a more lasting and safe treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115531419B_ABST
    Figure CN115531419B_ABST
Patent Text Reader

Abstract

The present invention relates to an active substance, namely, the use of amniotic epithelial cell-derived extracellular vesicles to promote hair growth by stimulating hair follicles. The present invention proves through a series of experiments that hAEC-EVs can significantly promote the transformation of hair follicles in the resting phase to hair follicles in the growth phase to promote hair regeneration. Therefore, hAEC-EVs has broad application prospects in promoting hair growth.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to the application of an active substance, and more particularly to the application of extracellular vesicles derived from amniotic epithelial cells in promoting hair growth. Background Art

[0002] Hair loss is a common disease caused by a variety of factors, such as aging, disease, and medication, and is characterized by a shorter anagen phase and a longer telogen phase in hair follicles. Although hair loss is not life-threatening, it brings various negative social and psychological impacts to patients. Mature hair follicles are considered to be self-renewing micro-organs that are able to produce new hair shafts through a cycle consisting of anagen, catagen, and telogen. Hair follicle growth and cycle are regulated by a complex interaction between epithelial and mesenchymal cells and require the integration of multiple stimulatory and inhibitory signals. The follicular papilla plays an important role in epithelial cell activation during the hair growth cycle and produces activating factors that lead to the telogen / anagen transition. Studies have found that the hair follicles of many patients with hair loss are in the telogen phase, in which keratinocytes and dermal papilla (DP) cells, two important cells that regulate the hair cycle, are inactive. A variety of reasons lead to the inactivation of these key cells, which leads to the reduction of hair follicles and hair loss.

[0003] At present, the treatment methods for hair loss are mainly drug therapy or hair transplantation. However, drug therapy such as minoxidil and finasteride is not effective in some cases, requires continuous use to maintain hair growth and has adverse side effects (Gomes MJ, Martins S, Ferreira D, Segundo MA, Reis S. Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies. Int J Nanomedicine 2014; 9: 1231-42). Follicular unit transplantation is an expensive invasive procedure and is limited by a shortage of donor hair follicles.

[0004] Therefore, current treatments for hair loss, such as surgery and medication, do not meet the satisfaction of most patients. Hair follicle transplant surgery is limited by the shortage of donor hair, reduced cell viability, and the expensive and time-consuming nature of the procedure. In addition, due to the progressive nature of hair loss, the results of medication treatment are usually temporary.

[0005] Therefore, in the field, many studies are looking for more effective treatments by exploring hair regeneration and focusing on the development mechanism of hair follicles from the resting phase to the growth phase. Summary of the invention

[0006] The present invention aims to provide a new active factor that can be used to promote hair growth, namely, the therapeutic application of amniotic epithelial cell-derived extracellular vesicles (hAECs-EVs) in hair growth.

[0007] The present invention provides a use of an active factor, characterized in that:

[0008] The above-mentioned active factors are: extracellular vesicles derived from amniotic epithelial cells;

[0009] The above-mentioned use is: preparing medicine for promoting hair growth.

[0010] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0011] The above use may also be: preparing a drug for promoting the expression of hair growth activation factor.

[0012] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0013] The above-mentioned use can also be: preparing a drug for promoting hair regeneration of the skin by improving the skin tissue structure.

[0014] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0015] The above mentioned uses may also be:

[0016] preparing a drug for promoting β-catenin expression;

[0017] and / or

[0018] preparing a drug for promoting Lef1 expression;

[0019] and / or

[0020] preparing a drug for promoting Gli1 expression;

[0021] and / or

[0022] Prepare a drug for promoting PTCH1 expression.

[0023] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0024] The above-mentioned use may also be: preparing a drug for promoting the transformation of hair follicles in the resting phase to hair follicles in the growing phase.

[0025] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0026] The above mentioned uses may also be:

[0027] Preparation of drugs for activating the WNT signaling pathway;

[0028] and / or

[0029] Preparation of drugs for activating the Shh signaling pathway.

[0030] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0031] The above-mentioned use can also be: preparing a drug for promoting hair thickening;

[0032] and / or

[0033] Preparation of a medicament for increasing the growth rate of hair follicles.

[0034] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0035] The content of the above active factors in the drug is not less than 2 mg / ml.

[0036] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0037] The preparation method of the above active factor is:

[0038] S1. Cultivate the amniotic epithelial cells at passage 3-5 in a culture dish. When the cell density reaches 70%-80%, remove the complete medium containing serum, wash with buffer 2-3 times, and then replace with serum-free medium;

[0039] S2. After culturing in serum-free medium for more than 24 hours, the cell supernatant was collected, and the cells and cell debris in the culture supernatant were removed by centrifugation at 100-300g to collect the supernatant;

[0040] S3. Remove the precipitate by centrifugation at 2000-3000g and collect the supernatant;

[0041] S4. Discard the supernatant by centrifugation at 100,000-120,000 g, add buffer to the precipitate and resuspend it to obtain extracellular vesicles of amniotic epithelial cells.

[0042] Furthermore, the use of an active factor provided by the present invention is also characterized in that:

[0043] The preparation method of the above-mentioned amniotic epithelial cells is as follows:

[0044] Human amniotic epithelial cells were isolated from fresh amniotic tissue of healthy full-term pregnant women after trypsin digestion, resuspended in culture medium, inoculated in cell culture dishes and then cultured in a cell culture incubator;

[0045] When the cell confluence reached 70%-80%, the adherent cells were digested with trypsin for 2-3 minutes and resuspended in the culture medium. The cell density was readjusted and the cells were seeded in a cell culture dish and then cultured in a cell culture incubator.

[0046] Functions and effects of the present invention:

[0047] The application of the extracellular vesicles derived from amniotic epithelial cells provided by the present invention in promoting hair regeneration. The raw material source for preparing amniotic epithelial cells is healthy amnion. Compared with various other stem cells, they are more primitive in development and have stronger amplification ability. In particular, they have many advantages such as wide source, low acquisition cost, and strong controllability. The raw material source of amniotic epithelial cells is healthy amnion. The collection process is non-invasive and convenient, and the source of amnion is abundant, which can meet large-scale production; the method for separating and extracting extracellular vesicles derived from amnion epithelial cells is simple and effective.

[0048] The use of the amniotic epithelial cell-derived extracellular vesicles provided by the present invention in promoting hair regeneration can promote the transformation of resting hair follicles to growth phase and promote hair regeneration. The amniotic epithelial cell-derived extracellular vesicles can be used as cosmetics or pharmaceutical compositions that promote hair growth and will have broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 This is a light microscopic image of the human AECs in Example 1.

[0050] Figure 2 This is the immunofluorescence staining image of the amniotic epithelial cell-specific marker protein in Example 1.

[0051] Figure 3 This is the Western blot identification result of the specific marker protein of amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) in Example 1.

[0052] Figure 4 This is a graph showing the NTA identification results of the diameter of amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) in Example 1.

[0053] Figure 5 This is a graph showing the experimental results of promoting hair regeneration after the injection of amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) in Example 2.

[0054] Figure 6This is a graph showing the experimental results of HE staining of mouse skin after treatment with amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) in Example 2.

[0055] Figure 7 This is a graph showing the experimental results of the expression of WNT and SHH signaling molecules in the skin after treatment with amniotic epithelial cell-derived extracellular vesicles (hAEC-EVs) in Example 2. DETAILED DESCRIPTION

[0056] The present invention is further described below in conjunction with preferred embodiments. Those skilled in the art should understand that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0057] The instruments, reagents and materials used in the present invention are well known to those skilled in the art and can be purchased from commercial organizations. The methods used in the present invention, such as HE staining, Western blot, etc., are well known in the art and can be performed according to the description in textbooks or related documents, and will not be described in detail. The methods described in the specification of the present invention are performed with reference to the methods described in the present invention.

[0058] Example 1

[0059] Isolation and identification of extracellular vesicles from amniotic epithelial cells

[0060] 1. Isolation, culture and identification of human amniotic epithelial cells (hAECs)

[0061] Fresh amniotic tissue from healthy full-term parturients was digested with 0.25% trypsin for 15 min to separate human amniotic epithelial cells, which were resuspended in DMEM / F12 medium containing fetal bovine serum, inoculated into cell culture dishes, and cultured in a 37°C cell culture incubator containing 5% CO2. When the cell confluence reached 70%-80%, adherent cells were digested with 0.25% trypsin for 2 min and resuspended in DMEM / F12 medium containing fetal bovine serum, and the cell density was readjusted to 1×10 5 The cells were then inoculated into a cell culture dish and cultured in a 37°C cell culture incubator containing 5% CO2.

[0062] The cells of the third generation were taken for subsequent operation, and the amniotic epithelial cells were identified as follows: Figure 1 As shown, the P3 cells were observed under an optical microscope and the cell morphology was round or oval and showed a cobblestone-like growth. Figure 1 is a light microscopic image of human amniotic epithelial cells (hAECs). Figure 2 As shown, cultured P3 amniotic epithelial cells all expressed CK19, E-cadherin and SSEA-4. Figure 1 The results showed that hAECs with higher purity were obtained.

[0063] 2. Isolation and Identification of Human Amniotic Epithelial Cell-derived Extracellular Vesicles (hAEC-EVs)

[0064] (1) hAECs of P3-5 generations were cultured in a culture dish. When the cell fusion reached 60%, the cells were washed twice with PBS and replaced with DMED / F12 medium without exosome serum. After further culture for 48 h, the cell supernatant was collected and centrifuged at 300 g for 10 min to remove the cells and cell debris in the culture supernatant and collect the supernatant; the culture supernatant was centrifuged at 2000-3000 g for 20 min to remove the precipitate and collect the supernatant; the culture supernatant was centrifuged at 120000 g for 120 min and the supernatant was discarded. The precipitate was resuspended in PBS and the amniotic epithelial cell extracellular vesicles (hAEC-EVs) were obtained by ultrahigh-speed centrifugation.

[0065] (2) Western blot detection of hAEC-EVs specific markers

[0066] Add the same volume of cell lysate to hAEC-EVs, let stand on ice for 20 minutes, centrifuge at 12000×g for 15 minutes at 4°C, and the supernatant is the total protein of hAEC-EVs. Prepare 10% polyacrylamide gel electrophoresis separation gel and concentration gel, load 40μg per well, electrophoresis at 80V for 2h, transfer at 200mA for 1h, remove the PVDF membrane and soak it in 5% BSA for 1h, incubate the primary antibody CD63, CD9, Alix and Calnexin in a 4°C wet box overnight, wash 3 times with PBST, incubate the secondary antibody at 37°C for 1h, wash 3 times with PBST, and finally take pictures using the ECL chemiluminescence system. The results are as follows Figure 3 As shown, the specific markers CD63, CD9 and Alix were positively expressed in amniotic epithelial cell extracellular vesicles (hAEC-EVs).

[0067] (3) Analysis of the diameter of hAEC-EVs using nano-ion analyzer

[0068] The Nanosight analyzer was used for analysis. 500 μl of the diluted sample was taken and operated according to the instrument manual to measure the size and concentration of the particles. Figure 4 As shown, the diameters of most hAEC-EVs range from 70 nm to 190 nm.

[0069] Example 2

[0070] hAEC-EVs improve the skin tissue microenvironment and promote hair regeneration

[0071] The experimental animals were all 6-week-old C57BL / 6 mice weighing about 30 g. Rosin and paraffin were mixed and heated to melt and applied to the back of the mice with the long axis parallel to the spine. The application area was about 4 cm x 3 cm. After cooling and solidification, the skin was peeled off to remove the back hair. The skin color of the mice with successful modeling was pink, the surface was smooth, and there was no ulceration, melanin deposition, etc. The drug administration began after confirming the resting period (the skin on the back of the mouse was pink).

[0072] The mice with successful modeling were randomly divided into two groups, the experimental group (hAEC-EVs group) and the control group. There were 5 mice in each group. On the second day after modeling, 50 μl of hAEC-EVs (concentration of 2 mg / ml) or PBS was subcutaneously injected into 10 injection points on the left side of the dorsal skin of the mice. Images of the hair regeneration status of the depilated mice were collected on days 0, 7, 14 and 21 after treatment.

[0073] 1. Observation of hair regeneration

[0074] After local subcutaneous injection of hAEC-EVs, a digital camera was used to track and photograph hair regeneration in order to determine the hair regeneration effect.

[0075] The experimental results of hAEC-EVs promoting hair regeneration are as follows Figure 5 As shown, the hair regeneration in the hAECs group was higher than that in the control group on day 14. However, there was no significant difference between the treated side and the untreated side in the hAEC-EVs group. This indicates that hAEC-EVs promoted the transformation of hair follicles from the resting phase to the growth phase, significantly promoting hair regeneration.

[0076] 2. HE staining to observe the microstructure of skin tissue

[0077] After treatment, skin samples were collected from the injection site (left) and untreated site (right), fixed with 4% paraformaldehyde for 24 h, embedded in paraffin, and serially sectioned at a thickness of 5 μm.

[0078] like Figure 6 The hematoxylin and eosin (H&E) staining shown in the figure showed that the hAEC-EVs treatment group promoted skin thickening and hair bulb enlargement on both the treated and untreated sides compared with the control group, indicating that after hAEC-EVs treatment, the skin tissue structure was improved and hair regeneration in the skin was promoted.

[0079] 3. hAEC-EVs promote the expression of WNT and SHH signaling molecules in hair follicles in vivo

[0080] After treatment, samples were collected and immunofluorescence staining was performed to detect changes in the expression of WNT and SHH signaling molecules.

[0081] like Figure 7As shown, hAEC-EVs treatment promoted the expression of β-catenin, Lef1, Gli1, and PTCH1 in both the treated and untreated sides compared with the control group. However, there was no significant difference between the treated and untreated sides in the hAEC-EVs treatment group. These results indicate that hAEC-EVs increased the expression levels of hair growth activators.

[0082] The above results describe the principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. The present invention may be subject to various changes and improvements without departing from the spirit and scope of the present invention, and these changes and improvements fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A use of an active factor, characterized in that: The active factors are: extracellular vesicles derived from amniotic epithelial cells; The use is: preparing a drug for promoting hair growth; The preparation method of the active factor is: S1. Culture the amniotic epithelial cells at passage 3-5 in a culture dish. When the cell density reaches 60%, remove the DMEM / F12 medium containing fetal bovine serum, wash with buffer 2-3 times, and then replace with serum-free DMED / F12 medium. S2. After culturing in serum-free medium for more than 24 hours, the cell supernatant was collected, and the cells and cell debris in the culture supernatant were removed by centrifugation at 100-300g to collect the supernatant; S3. Remove the precipitate by centrifugation at 2000-3000g and collect the supernatant; S4. discard the supernatant by centrifugation at 100000-120000 g, add buffer to the precipitate and resuspend it to obtain extracellular vesicles of amniotic epithelial cells; The preparation method of the amniotic epithelial cells is as follows: Human amniotic epithelial cells were isolated from fresh amniotic tissue of healthy full-term pregnant women after trypsin digestion, resuspended in DMEM / F12 medium containing fetal bovine serum, inoculated into cell culture dishes and cultured in a cell culture incubator; When the cell confluence reached 70%-80%, the adherent cells were digested with trypsin for 2-3 min and resuspended in DMEM / F12 medium containing fetal bovine serum. The cell density was readjusted and inoculated into a cell culture dish and then cultured in a cell culture incubator; The diameter of the amniotic epithelial cell extracellular vesicle ranges from 70 nm to 190 nm.

2. The use of an active factor according to claim 1, characterized in that: The use may also be: preparing a drug for promoting the transition of the hair follicle cycle from the resting phase to the growing phase.

3. The use of an active factor according to claim 1, characterized in that: The use may also be: preparing a drug for promoting the thickening of hair follicles; and / or Preparation of a medicament for increasing the growth rate of hair follicles.

4. The use of an active factor according to any one of claims 1 to 3, characterized in that: The content of the active factor in the drug is not less than 2 mg / ml.